Cochrane Abstracts
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease__COPD__Edited__no_change_to_conclusions___comment_added_to_review. Accessed 01 October 2023.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease__COPD__Edited__no_change_to_conclusions___comment_added_to_review. Accessed October 1, 2023.
Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease__COPD__Edited__no_change_to_conclusions___comment_added_to_review
Long‐acting Muscarinic Antagonist (LAMA) Plus Long‐acting Beta‐agonist (LABA) Versus LABA Plus Inhaled Corticosteroid (ICS) for Stable Chronic Obstructive Pulmonary Disease [Internet]. In: Cochrane Abstracts. [cited 2023 October 01]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease__COPD__Edited__no_change_to_conclusions___comment_added_to_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
ID - 431206
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431206/all/Long‐acting_muscarinic_antagonist__LAMA__plus_long‐acting_beta‐agonist__LABA__versus_LABA_plus_inhaled_corticosteroid__ICS__for_stable_chronic_obstructive_pulmonary_disease__COPD__Edited__no_change_to_conclusions___comment_added_to_review
DB - Evidence Central
DP - Unbound Medicine
ER -
